(Q38704025)

5 September 2017

title

Nuclear receptors and drug metabolism for the personalization of cancer therapy (English)

1 reference

5 September 2017

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26789519%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Elena De Mattia

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26789519%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Giuseppe Toffoli

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26789519%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

author name string

Erika Cecchin

1

1 reference

5 September 2017

Elena De Mattia

2

1 reference

5 September 2017

Giuseppe Toffoli

3

1 reference

5 September 2017

language of work or name

English

0 references

publication date

20 January 2016

1 reference

Expert Opinion on Drug Metabolism & Toxicology

5 September 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26789519%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

volume

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26789519%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26789519%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

page(s)

291-306

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26789519%20AND%20SRC:MED&resulttype=core&format=json

ABCC5 and ABCG1 polymorphisms predict irinotecan-induced severe toxicity in metastatic colorectal cancer patients.

11 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141196

Refining the UGT1A haplotype associated with irinotecan-induced hematological toxicity in metastatic colorectal cancer patients treated with 5-fluorouracil/irinotecan-based regimens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141196

Clinical validity of a DPYD-based pharmacogenetic test to predict severe toxicity to fluoropyrimidines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141196

Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141196

Pharmacogenetics of ABC and SLC transporters in metastatic colorectal cancer patients receiving first-line FOLFIRI treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141196

Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141196

Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141196

Pharmacogenetics: from bench to byte--an update of guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141196

Pharmacogenetics of the nuclear hormone receptors: the missing link between environment and drug effects?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141196

Nuclear receptors in the multidrug resistance through the regulation of drug-metabolizing enzymes and drug transporters.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141196

Xenobiotic-sensing nuclear receptors involved in drug metabolism: a structural perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141196

Inflammation-mediated changes in drug transporter expression/activity: implications for therapeutic drug response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141196

The nuclear receptor superfamily: the second decade

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141196

Nuclear receptors PXR and CAR: implications for drug metabolism regulation, pharmacogenomics and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141196

Orphan nuclear receptors as targets for drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141196

Pregnane xenobiotic receptor in cancer pathogenesis and therapeutic response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141196

The pregnane X receptor binds to response elements in a genomic context-dependent manner, and PXR activator rifampicin selectively alters the binding among target genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141196

Regulation of gene expression by CAR: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141196

MTHFR polymorphisms in gastric cancer and in first-degree relatives of patients with gastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141196

Thymidylate synthetase mRNA levels are increased in liver metastases of colorectal cancer patients resistant to fluoropyrimidine-based chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141196

Methylenetetrahydrofolate reductase genotype in diffuse large B-cell lymphomas with and without hypermethylation of the DNA repair gene O6-methylguanine DNA methyltransferase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141196

Uridine diphosphoglucuronosyl transferase and methylenetetrahydrofolate reductase polymorphisms as genomic predictors of toxicity and response to irinotecan-, antifolate- and fluoropyrimidine-based chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141196

Pharmacogenomics of intrinsic and acquired pharmacoresistance in colorectal cancer: Toward targeted personalized therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141196

Pregnane X Receptor (PXR) expression in colorectal cancer cells restricts irinotecan chemosensitivity through enhanced SN-38 glucuronidation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141196

Irinotecan induces steroid and xenobiotic receptor (SXR) signaling to detoxification pathway in colon cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141196

PXR-mediated induction of P-glycoprotein by anticancer drugs in a human colon adenocarcinoma-derived cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141196

Association of pregnane X receptor with multidrug resistance-related protein 3 and its role in human colon cancer chemoresistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141196

Differential drug resistance acquisition to doxorubicin and paclitaxel in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141196

Regulation of drug resistance by human pregnane X receptor in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141196

Induction of multidrug resistance associated protein 2 in tamoxifen-resistant breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141196

Down-regulation of pregnane X receptor contributes to cell growth inhibition and apoptosis by anticancer agents in endometrial cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141196

Expanding the roles for pregnane X receptor in cancer: proliferation and drug resistance in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141196

Human pregnane X receptor and resistance to chemotherapy in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141196

Cross-talk between androgen receptor and pregnane and xenobiotic receptor reveals existence of a novel modulatory action of anti-androgenic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141196

Role of pregnane X receptor in control of all-trans retinoic acid (ATRA) metabolism and its potential contribution to ATRA resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141196

Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141196

Minor role of pregnane-x-receptor for acquired multidrug resistance in head and neck squamous cell carcinoma in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141196

Regulation of multidrug resistance proteins by genistein in a hepatocarcinoma cell line: impact on sorafenib cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141196

PXR-mediated P-glycoprotein induction by small molecule tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141196

The constitutive androstane receptor is a novel therapeutic target facilitating cyclophosphamide-based treatment of hematopoietic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141196

The role of nuclear receptors in pharmacokinetic drug-drug interactions in oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141196

Pharmacogenetics of the constitutive androstane receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141196

PXR: a xenobiotic receptor of diverse function implicated in pharmacogenetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141196

Genetics-Based Population Pharmacokinetics and Pharmacodynamics of Risperidone in a Psychiatric Cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141196

Role of pregnane X receptor in chemotherapeutic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141196

NR1I2 polymorphisms are related to tacrolimus dose-adjusted exposure and BK viremia in adult kidney transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141196

Tacrolimus population pharmacokinetic-pharmacogenetic analysis and Bayesian estimation in renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141196

Long-term changes in cyclosporine pharmacokinetics after renal transplantation in children: evidence for saturable presystemic metabolism and effect of NR1I2 polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141196

Influence of CYP3A5, ABCB1 and NR1I2 polymorphisms on prednisolone pharmacokinetics in renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141196

Explaining variability in tacrolimus pharmacokinetics to optimize early exposure in adult kidney transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141196

Intracellular accumulation of atazanavir/ritonavir according to plasma concentrations and OATP1B1, ABCB1 and PXR genetic polymorphisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141196

A population pharmacokinetic-pharmacogenetic analysis of atazanavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141196

Population pharmacokinetic modeling of the association between 63396C->T pregnane X receptor polymorphism and unboosted atazanavir clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141196

Association of a single-nucleotide polymorphism in the pregnane X receptor (PXR 63396C-->T) with reduced concentrations of unboosted atazanavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141196

PXR and CAR single nucleotide polymorphisms influence plasma efavirenz levels in South African HIV/AIDS patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141196

Association of warfarin dose with genes involved in its action and metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141196

Correlates of efavirenz exposure in Chilean patients affected with human immunodeficiency virus reveals a novel association with a polymorphism in the constitutive androstane receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141196

Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141196

Effects of Pregnane X Receptor Genetic Polymorphisms on Stable Warfarin Doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141196

Genetic variation in ABCB1 influences paclitaxel pharmacokinetics in Japanese patients with ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141196

Polymorphisms in SLCO1B3 and NR1I2 as genetic determinants of hematotoxicity of carboplatin and paclitaxel combination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141196

Lack of association of single-nucleotide polymorphisms in pregnane X receptor, hepatic nuclear factor 4alpha, and constitutive androstane receptor with docetaxel pharmacokinetics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141196

PXR, CAR and HNF4alpha genotypes and their association with pharmacokinetics and pharmacodynamics of docetaxel and doxorubicin in Asian patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141196

Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxel-induced leukopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141196

Pharmacogenetic effects of regulatory nuclear receptors (PXR, CAR, RXRα and HNF4α) on docetaxel disposition in Chinese nasopharyngeal cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141196

PXR pharmacogenetics: association of haplotypes with hepatic CYP3A4 and ABCB1 messenger RNA expression and doxorubicin clearance in Asian breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141196

Role of pharmacogenetics on adjuvant chemotherapy-induced neutropenia in Chinese breast cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141196

Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141196

Role of the lean body mass and of pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of sunitinib in cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141196

Relationship of systemic exposure to unbound docetaxel and neutropenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141196

The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141196

A role for the pregnane X receptor in flucloxacillin-induced liver injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141196

Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141196

Polymorphisms in the ABCB1 gene and effect on outcome and toxicity in childhood acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141196

High resolution melting analysis of the NR1I3 genetic variants: Is there an association with neonatal hyperbilirubinemia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141196

Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141196

Epigenetic mechanisms of importance for drug treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141196

miRNA pharmacogenomics: the new frontier for personalized medicine in cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141196

Post-transcriptional regulation of human pregnane X receptor by micro-RNA affects the expression of cytochrome P450 3A4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141196

Genetic variation in the 3'-UTR of CYP1A2, CYP2B6, CYP2D6, CYP3A4, NR1I2, and UGT2B7: potential effects on regulation by microRNA and pharmacogenomics relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141196

Nuclear receptors as drug targets for metabolic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141196

Solomonamides A and B, new anti-inflammatory peptides from Theonella swinhoei.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141196

Pharmacogenetics of CYP1A2 activity and inducibility in smokers and exsmokers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2016.1141196

10.1517/17425255.2016.1141196

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26789519%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

1 reference